In a trial of 20,330 girls aged 12 to 16 in Costa Rica, one dose of either the bivalent or the nonavalent HPV vaccine protected against HPV 16 and 18 infection as well as two doses.
ESCUDDO randomised girls aged 12 to 16, in a 1:1:1:1 ratio, to one or two doses of a bivalent or a nonavalent HPV vaccine. The primary end point was new HPV 16 or 18 infection from month 12 to month 60 persisting for at least 6 months, with a noninferiority margin of 1.25 infections per 100 participants. Vaccine effectiveness was estimated against 3,005 unvaccinated girls and women in a parallel survey. The trial was funded by the US National Cancer Institute and others; ClinicalTrials.gov lists its site at ACIB in Liberia, Guanacaste.
One dose of HPV vaccine protected girls against infection with HPV 16 and 18, the two types that cause most cervical cancers, as well as two doses did, so the same supply of vaccine could protect more girls.
Shares Agencia Costarricense de Investigaciones Biomédicas, Fundación INCIENSA (ACIB-FUNIN), HPV bivalent vaccine (types 16 and 18), National Cancer Institute (NIH), Cervical cancer.
Shares Agencia Costarricense de Investigaciones Biomédicas, Fundación INCIENSA (ACIB-FUNIN), HPV bivalent vaccine (types 16 and 18), National Cancer Institute (NIH), Cervical cancer.
Shares HPV bivalent vaccine (types 16 and 18), Cervical cancer.
Shares HPV bivalent vaccine (types 16 and 18), Cervical cancer.
Shares HPV bivalent vaccine (types 16 and 18), Nonavalent HPV vaccine, Cervical cancer.
Shares Agencia Costarricense de Investigaciones Biomédicas, Fundación INCIENSA (ACIB-FUNIN), Cervical cancer.
Shares Nonavalent HPV vaccine, National Cancer Institute (NIH), Cervical cancer.
Shares Nonavalent HPV vaccine, Cervical cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/